Inclusive of all taxes
BORTLIEVA (Bortezomib Injection IP 3.5mg per vial) is a highly effective proteasome inhibitor indicated for the treatment of multiple myeloma and mantle cell lymphoma. Manufactured by Allieva Pharma Private Limited in India, this injectable anti-cancer medicine is designed for intravenous or subcutaneous administration under strict medical supervision. Bortezomib works by inhibiting proteasome activity in cancer cells, leading to apoptosis and reduction of tumor burden. It is utilized in adults for newly diagnosed or relapsed/refractory multiple myeloma, as well as for previously treated mantle cell lymphoma patients, and occasionally combined with other chemotherapy agents for hematologic cancers. BORTLIEVA is supplied in 3.5 mg vials, with dosing protocols typically involving 1.3 mg/m² administered on Days 1, 4, 8, and 11 in a 21-day cycle, adjustable per patient tolerance and response. Common side effects include neuropathy, gastrointestinal disturbances, fatigue, and low blood cell counts, while serious adverse events necessitate vigilant monitoring of blood parameters and liver function. As a prescription-only, scheduled anti-cancer drug, BORTLIEVA offers oncologists a reliable therapeutic option backed by proven pharmacological efficacy and regulatory compliance.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Bortezomib Injection IP 3.5mg |
| Therapeutic Use | Treatment of Multiple Myeloma and Mantle Cell Lymphoma |
| Administration Route | Intravenous (IV) or Subcutaneous (SC) injection |
| Dosage Form | Injection in 3.5 mg vial |
| Manufacturer | Allieva Pharma Private Limited |
| Country of Origin | India |
| Prescription Status | Prescription required; Scheduled drug |
| Packaging | Single Vial per Piece |
| Mechanism of Action | Proteasome inhibitor causing cancer cell apoptosis |
| Typical Dosage Regimen | 1.3 mg/m² on Days 1, 4, 8, 11 in a 21-day cycle |
| Attributes | Description |
|---|---|
| Product Name | BORTLIEVA (Bortezomib Injection IP 3.5mg) |
| Dosage Strength | 3.5 mg per vial |
| Active Pharmaceutical Ingredient (API) | Bortezomib |
| Formulation | Injection |
| Route of Administration | IV / SC |
| Therapeutic Category | Anti-Cancer, Oncology |
| Indications | Multiple Myeloma, Mantle Cell Lymphoma |
| Manufacturer | Allieva Pharma Private Limited |
| Country of Origin | India |
| Prescription Requirement | Yes |
| Packaging Type | Vial |
| MOQ | 1 Piece |
| Storage Conditions | Store as per physician's instructions |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
BORTLIEVA is indicated for treating multiple myeloma—both newly diagnosed and relapsed/refractory—and mantle cell lymphoma in previously treated patients.
It can be administered either intravenously (IV) or subcutaneously (SC) in cycles, typically 1.3 mg/m² on Days 1, 4, 8, and 11 of a 21-day treatment cycle.
BORTLIEVA must be stored as per the manufacturer’s and physician’s recommendations to maintain stability, typically in a controlled temperature environment.
Common side effects include fatigue, peripheral neuropathy, nausea, vomiting, diarrhea or constipation, and blood count abnormalities such as thrombocytopenia and neutropenia.
Yes, BORTLIEVA is a prescription-only and scheduled anti-cancer drug, requiring authorization from a licensed healthcare professional.
Country Of Origin: India
Inclusive of all taxes
You Save: 0
